U.S. Multi-Site
AVALON
AVALON is a phase 1 clinical trial assessing the investigational drug VTP-1000 in adults with celiac disease.
This investigational targeted immunotherapy is designed to prevent or reduce symptoms from accidental gluten exposure by promoting tolerance to gluten.
Eligibility Criteria:
- 18–65 years old
- Celiac disease confirmed by biopsy within the past 10 years
- Have been on a gluten-free diet for 12+ months
- US resident
Additional criteria apply, and compensation for your time and travel may be available.
Learn more at avalon.celiac.org.